Tarceva is used in advanced cancer or metastatic cancer (when cancer cells have spread from the original site to other parts of the body), when at least one
Tarceva has not been shown to be effective in patients whose tumours are "EGFR-negative’.
"EGFR-negative’ means that some receptors, the epidermal growth factor receptors (EGFR), cannot be detected on the surface of the cancer cells, or can only be detected in small quantities.  metastatic pancreatic cancer, in combination with gemcitabine (another anticancer medicine).
How is Tarceva used?
Treatment with Tarceva should be supervised by a doctor who has experience of the use of anticancer medicines.
